PSTV (Plus Therapeutics) ROCE % : 0.00% (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Plus Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.

Plus Therapeutics ROCE % Historical Data

The historical data trend for Plus Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics ROCE % Chart

Plus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-18.82

-115.92

-126.72

-139.12

-203.87

Plus Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-452.44	-881.62	-	-	-

Plus Therapeutics ROCE % Calculation

Plus Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-12.921	/	( ( (23.867 - 11.852)	+	(11.388 - 10.727) )	/ 2 )
	=	-12.921	/	( (12.015	+	0.661)	/ 2 )
	=	-12.921	/	6.338
	=	-203.87 %

Plus Therapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-11.252	/	( ( (11.212 - 18.787)	+	(6.978 - 12.112) )	/ 2 )
	=	-11.252	/	( ( -7.575	+	-5.134 )	/ 2 )
	=	-11.252	/	-6.3545
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Plus Therapeutics (NAS:PSTV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Plus Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Plus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

XMP0:Germany XMP0:Germany

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.plustherapeutics.com

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Executives

Richard J Hawkins	director	950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Greg Petersen	director	3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Howard Clowes	director	217 DWIGHT ROAD, BURLINGAME CA 94010
Marc H Hedrick	officer: President	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Sims Andrew John Hugh Macintyre	officer: Chief Financial Officer	4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Robert P Lenk	director	LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Norman D. Lafrance	officer: CHIEF MEDICAL OFFICER	MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van	director	6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance	10 percent owner	MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote	10 percent owner	CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell	director	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino	officer: Chief Medical Officer	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris	officer: VP and GM of Cell Therapy	3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974